Gubra AS (FRA:PI3) EPS without NRI: €13.77 (TTM As of Dec. 2025)


FRA:PI3 Gubra AS FRA:PI3
73 GF Score
Price €44.00
GF Value €372.36
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Gubra AS EPS without NRI?

Gubra AS FRA:PI3 +1.85% 73 EPS without NRI is €13.77 as of Dec. 2025. GuruFocus rates FRA:PI3 with a GF Score™ of 73/100 and a GF Value™ of €372.36 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,170 Biotechnology companies, Gubra AS ranks better than 99.91% on this metric.

Gubra AS's earnings per share without non-recurring items for the six months ended in Dec. 2025 was €-0.59. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was €13.77.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 617.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Gubra AS's EPS without NRI or its related term are showing as below:

FRA:PI3' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 617   Med: 617   Max: 617
Current: 617

During the past 7 years, Gubra AS's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 617.00% per year. The lowest was 617.00% per year. And the median was 617.00% per year.

FRA:PI3's 3-Year EPS without NRI Growth Rate is ranked better than
99.91% of 1170 companies
in the Biotechnology industry
Industry Median: 16.75 vs FRA:PI3: 617.00

Gubra AS's EPS (Diluted) for the six months ended in Dec. 2025 was €-0.59. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €13.77.

Gubra AS's EPS (Basic) for the six months ended in Dec. 2025 was €-0.58. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €13.91.


Gubra AS  (FRA:PI3) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Gubra AS EPS without NRI Related Terms


Gubra AS EPS without NRI Historical Data

* Premium members only.

The historical data trend for Gubra AS's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gubra AS EPS without NRI Chart

Gubra AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial 0.56 0.04 -0.39 -0.30 13.03

Gubra AS Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.22 -0.16 -0.13 14.36 -0.59

FRA:PI3 vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Gubra AS's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gubra AS PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gubra AS's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Gubra AS's PE Ratio without NRI falls into.


FRA:PI3
73GF Score
Gubra AS FRA:PI3
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gubra AS EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €13.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €13.77 mean?
Gubra AS (FRA:PI3) has a EPS without NRI of €13.77 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Gubra AS and its competitors. According to the industry distribution chart, Gubra AS ranks #1 out of 1170 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is Gubra AS's EPS without NRI too high?
Gubra AS's current EPS without NRI is €13.77. Based on the distribution chart, Gubra AS ranks #1 out of 1170 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gubra AS has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gubra AS ranks #1 out of 1170 companies for EPS without NRI. This places Gubra AS in the top 0% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.75, based on 1,170 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Gubra AS and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gubra AS's current EPS without NRI is €13.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Based on GuruFocus' analysis, Gubra AS (FRA:PI3) is currently considered Possible Value Trap. The stock's GF Value™ is €372.36, compared to a current price of €44.00 — trading 88.2% below its estimated fair value. The current EPS without NRI is €13.77. Gubra AS's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Gubra AS (FRA:PI3), the current EPS without NRI is €13.77 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gubra AS (FRA:PI3) Overvalued in 2026?

Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued. The current stock price of €44.00 is trading 88.2% below its estimated GF Value™ of €372.36. GuruFocus considers Gubra AS to be Possible Value Trap.

Key valuation signals for FRA:PI3:

  • EPS without NRI: €13.77
  • GF Value™: €372.36 vs. price of €44.00 (88.2% below fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the FRA:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gubra AS Business Description

Other Exchanges GUBRA:DenmarkPI3:Germany
Address Horsholm Kongevej 11B, Horsholm, DNK, 2970
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
73GF Score

Get the complete analysis for FRA:PI3

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€44.00
Price
€372.36
GF Value